Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment…
Other actions, Approvals and indications & Adverse effects
Explore the main themes, entities and connections around Regorafenib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
patients cancer advanced us effects stromal names approved treated tyrosine kinase liver clinical actions brand approvals name stivarga growth studies
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Regorafenib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Regorafenib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Regorafenib | ATC code | L01EX05 (WHO) | 1.00 | infobox |
| Regorafenib | Bioavailability | 69-83% | 1.00 | infobox |
| Regorafenib | CAS Number | 755037-03-7 | 1.00 | infobox |
| Regorafenib | ChEBI | CHEBI:68647 | 1.00 | infobox |
| Regorafenib | ChEMBL | ChEMBL1946170 | 1.00 | infobox |
| Regorafenib | ChemSpider | 9342697 | 1.00 | infobox |
| Regorafenib | CompTox Dashboard (EPA) | DTXSID60226441 | 1.00 | infobox |
| Regorafenib | DrugBank | DB08896 | 1.00 | infobox |
| Regorafenib | ECHA InfoCard | 100.248.939 | 1.00 | infobox |
| Regorafenib | Elimination half-life | 20-30 hours | 1.00 | infobox |
| Regorafenib | Excretion | Feces (71%), urine (19%) | 1.00 | infobox |
| Regorafenib | Formula | C21H15ClF4N4O3 | 1.00 | infobox |
| Regorafenib | KEGG | D10138 | 1.00 | infobox |
| Regorafenib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Regorafenib | Legal status | CA: ℞-only | 1.00 | infobox |
| Regorafenib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Regorafenib | Legal status | US: ℞-only | 1.00 | infobox |
| Regorafenib | Legal status | EU: Rx-only | 1.00 | infobox |
| Regorafenib | License data | US DailyMed: Regorafenib | 1.00 | infobox |
| Regorafenib | MedlinePlus | a613004 | 1.00 | infobox |
| Regorafenib | Metabolism | Liver (UGT1A9-mediated) | 1.00 | infobox |
| Regorafenib | Molar mass | 482.82 g·mol−1 | 1.00 | infobox |
| Regorafenib | Other names | BAY 73-4506 | 1.00 | infobox |
| Regorafenib | Pregnancy category | AU: D | 1.00 | infobox |
| Regorafenib | Protein binding | 99.5% | 1.00 | infobox |
| Regorafenib | PubChem CID | 11167602 | 1.00 | infobox |
| Regorafenib | Routes of administration | By mouth | 1.00 | infobox |
| Regorafenib | Trade names | Stivarga, Regonix | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.